Publications by authors named "Jan Wienhold"
Andexanet alfa is a specific antidote for factor Xa (FXa) inhibitors. It is licensed to treat patients under FXa inhibitor therapy with life-threatening bleeding. Concomitantly, volume expanders are used to compensate for blood loss and maintain circulation.
View Article and Find Full Text PDFArticle Synopsis
- - The introduction of direct oral anticoagulants (DOACs) has improved anticoagulant treatments, but they can also increase the risk of severe bleeding, complicating treatment, especially after injuries.
- - Recent studies highlight the importance of quickly reversing DOAC effects during major bleeding, showing that antidotes like andexanet alfa and idarucizumab, as well as prothrombin complex concentrates (PCCs), can effectively counteract these effects.
- - Current guidelines suggest using specific antidotes and PCCs for managing major bleeding related to DOACs, but more randomized trials are needed to better understand their effectiveness and safety in this context.
In Germany, approximately 17 million anaesthesiological procedures and, consequently, roughly the same number of preoperative consultations are conducted each year. So far, these have predominantly taken place in person. However, recent developments in technology, medical-legal aspects, and politics, combined with the catalyzing effect of the pandemic situation, have led to a significant boost in telemedicine.
View Article and Find Full Text PDFBackground: During the surge in coronavirus disease 2019 (COVID-19) infections in early 2020, many medical organisations began developing strategies for implementing teleconsultation to maintain medical services during lockdown and to limit physical contact. Therefore, we developed a teleconsultation preoperative evaluation platform to replace on-site preoperative meetings.
Objective: This study assessed the feasibility of a teleconsultation for preoperative evaluation and procedure-associated adverse events.